 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
109 News |  |
| «12 |
- ||| temelimab (GNbAC1) / GeNeuro
Trial completion: RAINBOW-T1D: Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years (clinicaltrials.gov) - May 22, 2019
P2, N=64, Completed, Sponsor: GeNeuro Australia PTY Ltd
Active, not recruiting --> Completed
- || temelimab (GNbAC1) / GeNeuro
Trial completion: Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers (clinicaltrials.gov) - May 22, 2019
P1, N=24, Completed, Sponsor: GeNeuro Australia PTY Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | GNbAC1 / Servier, GeNeuro
Journal: Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination. (Pubmed Central) - May 16, 2019
Therefore, our study provides mechanistic insights into oligodendroglial inhibition processes and presents three different means to counteract the anti-myelination effect of the ENV protein. These observations are therefore of interest in light of understanding the complexity of the numerous oligodendroglial inhibitors and might promote the establishment of novel regenerative therapies.
- |||||| temelimab (GNbAC1) / GeNeuro
Trial completion date, Trial termination, Trial primary completion date: ANGEL-MS: Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis (clinicaltrials.gov) - Dec 12, 2018
P2, N=220, Terminated, Sponsor: GeNeuro SA
These observations are therefore of interest in light of understanding the complexity of the numerous oligodendroglial inhibitors and might promote the establishment of novel regenerative therapies. Trial completion date: Dec 2019 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Nov 2018; Based on R&D strategic reasons, our co-development Partner financing the study disengaged from the development of GNbAC1.
- | temelimab (GNbAC1) / GeNeuro
Enrollment closed: Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers (clinicaltrials.gov) - Sep 18, 2018
P1, N=24, Active, not recruiting, Sponsor: GeNeuro Australia PTY Ltd
Trial completion date: Dec 2019 --> Nov 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Nov 2018; Based on R&D strategic reasons, our co-development Partner financing the study disengaged from the development of GNbAC1. Recruiting --> Active, not recruiting
- | temelimab (GNbAC1) / GeNeuro
New P1 trial: Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers (clinicaltrials.gov) - Jul 15, 2018
P1, N=24, Recruiting, Sponsor: GeNeuro Australia PTY Ltd
- | temelimab (GNbAC1) / GeNeuro
Enrollment closed: RAINBOW-T1D: Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years (clinicaltrials.gov) - Jan 23, 2018
P2, N=60, Active, not recruiting, Sponsor: GeNeuro Australia PTY Ltd
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| temelimab (GNbAC1) / GeNeuro
Trial completion: CHANGE-MS: Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS (clinicaltrials.gov) - Jan 3, 2018
P2b, N=270, Completed, Sponsor: GeNeuro SA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| temelimab (GNbAC1) / GeNeuro
New P2 trial: ANGEL-MS: Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis (clinicaltrials.gov) - Aug 3, 2017
P2, N=200, Recruiting, Sponsor: GeNeuro SA
- | temelimab (GNbAC1) / GeNeuro
New P2 trial: RAINBOW-T1D: Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years (clinicaltrials.gov) - Jun 7, 2017
P2, N=60, Recruiting, Sponsor: GeNeuro Australia PTY Ltd
- ||| temelimab (GNbAC1) / GeNeuro
Enrollment closed: CHANGE-MS: Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS (clinicaltrials.gov) - May 5, 2017
P2b, N=260, Active, not recruiting, Sponsor: GeNeuro SA
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | temelimab (GNbAC1) / GeNeuro
New P2b trial: CHANGE-MS: Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS (clinicaltrials.gov) - May 25, 2016
P2b, N=260, Recruiting, Sponsor: GeNeuro SA
- | temelimab (GNbAC1) / GeNeuro
Trial completion: Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers (clinicaltrials.gov) - Aug 20, 2015
P1, N=21, Completed, Sponsor: GeNeuro Innovation SAS
Recruiting --> Active, not recruiting Recruiting --> Completed
- | temelimab (GNbAC1) / GeNeuro
New P1 trial: Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers (clinicaltrials.gov) - May 26, 2015
P1, N=21, Recruiting, Sponsor: GeNeuro Innovation SAS
- temelimab (GNbAC1) / GeNeuro
Trial completion, IO biomarker: Safety Study of GNbAC1 in Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 27, 2014
P2, N=10, Completed, Sponsor: GeNeuro Innovation SAS
Recruiting --> Completed Active, not recruiting --> Completed
- | temelimab (GNbAC1) / GeNeuro
New P1 trial, First-in-human: First-in-Human Study With GNbAC1 in Healthy Volunteers (clinicaltrials.gov) - Oct 1, 2012
P1, N=33, Completed, Sponsor: GeNeuro Innovation SAS
- temelimab (GNbAC1) / GeNeuro
New P2 trial, IO biomarker: Safety Study of GNbAC1 in Multiple Sclerosis Patients (clinicaltrials.gov) - Jul 10, 2012
P2, N=10, Completed, Sponsor: GeNeuro Innovation SAS